ITIH1 Antibody, HRP conjugated consists of a polyclonal antibody specific to human ITIH1, chemically linked to HRP. The antibody targets epitopes within amino acids 403–638 of the ITIH1 protein . Its mechanism involves:
Antigen capture: Pre-coated primary antibodies immobilize ITIH1 in microplate wells.
Signal amplification: HRP catalyzes a colorimetric reaction using TMB substrate, producing measurable optical density proportional to ITIH1 concentration .
Tumor Suppression Studies: ITIH1 knockdown in renal cell carcinoma (RCC) cells increased proliferation (p<0.05) and invasion, while overexpression suppressed these effects .
Pathway Analysis: ITIH1 modulates NF-κB signaling; inhibition with JSH-23 reversed pro-tumorigenic effects in RCC .
Clinical Samples: Validated for use in serum, plasma, and tissue homogenates with recovery rates of 85–105% .
Specificity: Demonstrated high specificity for human ITIH1, though cross-reactivity with homologs remains incompletely characterized .
Precision: Intra- and inter-assay coefficients of variation (CV) ≤10% ensure reproducibility .